AbbVie seeks FDA approval for tavapadon to treat Parkinson’s

AbbVie has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration for tavapadon, a novel selective dopamine D1/D5 receptor partial agonist being studied as a once-daily oral treatment for Parkinson’s disease, according to the company. The submission is backed by data from the TEMPO clinical development program, which comprises three Phase […] The post AbbVie seeks FDA approval for tavapadon to treat Parkinson’s appeared first on Longevity.Technology.